With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind shot.

The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026 ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...

Vaccine manufacturer Moderna said Wednesday the US Food and Drug Administration walked back its previous position and agreed to review the company's new mRNA-based flu shot. Last week the US firm said ...

Shares of Moderna surged Wednesday after the drugmaker got health regulators to change their minds and start reviewing the biotechnology company’s flu-vaccine candidate for potential approval. The ...